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CASE PRESENTATION
A 55-year-old Caucasian woman presented to her primary
care physician with complaints of progressive fatigue for
several months, dyspnea with minimal exertion, loss of
appetite, 15-pound weight loss, and recurrent low-grade
fevers. Past medical history was significant only for
migraine headaches. The patient was taking no
prescription or over-the-counter medications. There was
no history of environmental toxin exposure, recent travel,
smoking, excess alcohol consumption, or use of illicit
drugs. She was empirically treated with a course of
esomeprazole and amoxicillin.
The patient returned 2 weeks later and reported no
improvement in her symptoms. Laboratory studies
revealed anemia, thrombocytopenia, hypercalcemia, and
acute renal failure. The patient was admitted for further
evaluation.
Upon admission, physical examination revealed a well
nourished but pale female in no acute distress. Her blood
pressure was 156/70mmHg, pulse 96bpm, temperature
98.6 F, respiratory rate 20breaths/min, and pulse oximetry
100% on room air. Cardiac and pulmonary examinations
were unremarkable. Abdominal examination revealed
splenomegaly with a palpable liver edge 1–2 cm below the
right costal margin. Laboratory testing (Table 1) was
notable for a hemoglobin of 6.1 g/dl (normal range,
11.0–15.0g/dl), platelet count 112K/mm3 (nl 150–400K/
mm3), creatinine 3.7mg/dl, BUN 34mg/dl, and calcium
12.4mg/dl (nl 8.5–10.1mg/dl). Liver function tests,
coagulation studies, and parathyroid hormone levels were
normal. Urinalysis revealed 1þ protein, 1þ glucose, and
trace blood. Negative serologies included anti-glomerular
basement membrane antibody, proteinase-3 anti-
neutrophil cytoplasmic antibodies, and myeloperoxidase
anti-neutrophil cytoplasmic antibodies. Serum
complement levels were mildly elevated with C3
179.0mg/dl (nl 75–135mg/dl) and C4 41.9mg/dl (nl
9–36mg/dl). Serum protein electrophoresis with
immunofixation showed no monoclonal protein. A bone
marrow biopsy revealed normocellular marrow with no
evidence of lymphoma or a plasma cell dyscrasia. A non-
contrast computed tomography scan of the chest,
abdomen, and pelvis was notable for splenomegaly
(18 15 10 cm) with a hypodense area measuring
7 7 4 cm and mild hepatomegaly. The kidneys
measured 11.7 and 12 cm in length by ultrasound, without
evidence of obstruction. A skeletal survey showed no
abnormalities.
The patient was treated with hydration and a single
dose of pamidronate. At the time of discharge 6 days later,
her creatinine had fallen to 1.9mg/dl, and her calcium had
normalized.
The patient was seen in nephrologic consultation 1
week after discharge, at which time her creatinine had
declined to 1.5mg/dl. Computed tomography scan was
repeated with contrast and revealed a 19 16 10 cm
spleen with an ill-defined 11 11 13 cm mass with areas
of probable necrosis. In light of the absence of a clear
indication for splenectomy, a renal biopsy was performed
to determine the cause of the patient’s persistent renal
dysfunction.
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RENAL BIOPSY FINDINGS
The renal biopsy was processed for light microscopy,
immunofluorescence (IF), and electron microscopy, according
to standard techniques. Sampling for light microscopy included
two cores of renal cortex containing 14 glomeruli, one of which
was globally sclerotic. Glomeruli appeared histologically
unremarkable. Proximal tubules displayed mild degenerative
changes characterized by luminal ectasia, cytoplasmic simpli-
fication with vacuolization, and prominent nucleoli. The
degenerative changes in proximal tubules were accompanied
by intracellular inclusions, which appeared pale with the
hematoxylin and eosin and PAS stains and multifocally formed
cleft-like spaces (Figure 1a). There was mild interstitial
inflammation composed of mainly lymphocytes and rare foci
of mild tubulitis. There was moderate tubular atrophy and
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interstitial fibrosis involving approximately 40% of the cortex
sampled. Vessels exhibited mild arteriosclerosis. Congo red
staining for amyloid was negative.
Sampling for IF consisted of 5 glomeruli and exhibited no
significant glomerular positivity for IgG, IgM, IgA, C3, C1,
fibrinogen, albumin, or k or l light chains. There were rare
tubular casts, which stained similarly for IgA, k, and l.
Following review of the ultrastructural findings, immuno-
flourescence staining was repeated following pronase diges-
tion and revealed intracellular needle-shaped crystals in
proximal tubules which stain positive for k and negative for l
(Figure 1b).
The predominant abnormalities seen on ultrastructural
evaluation involved the proximal tubules. In addition to
tubular degenerative changes, proximal tubules contained
abundant intracellular and focal intraluminal crystalline
inclusions. The inclusions had a fibrillar appearance and
formed parallel arrays and groupings. A minority of the
inclusions were found to lie in membrane-bound structures
(Figure 1c and d). Glomeruli exhibited no significant
ultrastructural abnormalities. There was no significant foot
process effacement and no electron dense deposits were
apparent.
Renal biopsy diagnosis: light chain proximal tubulopathy,
j-type (a.k.a. Light chain Fanconi syndrome)
Clinical follow-up No. 1. Following receipt of the renal
biopsy results, serum free light chain testing was performed
and showed a free k level of 25.20 (nl 3.30–19.40mg/l), free l
of 28.10 (nl 5.71–26.30mg/l), and a normal k/l ratio of 0.9
(nl 0.26–1.65). Urine protein electrophoresis with immuno-
fixation showed a monoclonal k Bence Jones protein. Light
chain Fanconi syndrome (LCFS) is mainly associated with
multiple myeloma (MM), which does not typically involve
the spleen. Nonetheless, in light of the presence of a
monoclonal urine spike and the renal biopsy findings,
splenectomy was performed.
SPLENECTOMY FINDINGS
Due to direct extension of the splenic mass into the distal
pancreas, combined splenectomy with distal pancreatectomy
was performed. Grossly, the splenic parenchyma was almost
entirely replaced by a yellow-grey soft mass with a necrotic
center. The mass extended into the tail of the pancreas and
into peripancreatic adipose tissue.
Microscopic evaluation of the splenic and distal pancreatic
mass showed a diffuse, dense sheet-like infiltrate of
pleomorphic medium- to large-sized lymphocytes and zones
of coagulative necrosis. The lymphocytes exhibited round to
ovoid vesicular nuclei with variably multiple small or single
prominent nucleoli. In a few areas, the lymphocytes showed
plasmacytoid morphology (Figure 2a). Scattered tingible-
body macrophages were present. The neoplastic cells
expressed CD20 (Figure 2b), Pax-5, and CD79a (B-cell
markers), BCL2, and subsets showed either BCL6 or MUM1
expression (markers of germinal center B cells and activated
lymphocytes or plasma cells, respectively). Nuclear staining
for p53 was observed in 30% of cells. The cells showed a
high proliferation index (80%) on staining for Ki-67/MIB1.
The neoplastic cells did not express CD3 or CD5 (T-cell
markers), CD10, CD23, CD138 (a mature plasma cell
marker), or CD43. In situ hybridization for immunoglobulin
light chain mRNA showed cytoplasmic k light chain
restriction (Figure 2c and d). No EBER positive cells were
seen by in situ hybridization. The morphology and phenotype
were consistent with a diffuse large B-cell lymphoma,
‘activated’ or non-germinal center type. The variability in
cell size and p53 expression raised the possibility of
transformation from a prior low-grade lymphoma such as a
primary splenic marginal zone lymphoma or a lymphoplas-
macytic lymphoma, but no distinct low-grade component was
identified.
SPLENECTOMY DIAGNOSIS
Diffuse large B-cell lymphoma with plasmacytoid features
Clinical follow-up No. 2. Following splenectomy, the
patient’s creatinine declined over 4 days from 1.6 to 1.2mg/dl.
Over the following 3 weeks, the creatinine declined further to
0.8mg/dl, at which point the patient began chemotherapy.
Four months later, following 6 cycles of chemotherapy with
CHOP (cyclophosphamide, adriamycin, vincristine, and
prednisolone) and Rituximab, the patient has a creatinine
of 1.0mg/dl (Figure 3). A follow-up positron emission
tomography scan showed resolution of a previous area of
positivity in the left iliac crest that was discovered in the
initial staging of the diffuse large B-cell lymphoma.
Table 1 | Laboratory data at initial hospital admission
Laboratory tests Results (normal values)
Hemogram
WBC 5.58 (4.0–10.0 K/mm3)
Hemoglobin 6.1 (11.0–15.0 g/dl)
Platelet count 112 (150–400 K/mm3)
Sodium 138 (136–145meq/l)
Potassium 3.3 (3.5–5.1meq/l)
Chloride 102 (102–110meq/l)
CO2 27 (22–29meq/l)
Glucose 104 (70–110mg/dl)
Calcium 12.4 (8.5–10.1mg/dl)
BUN 34 (7–23mg/dl)
Creatinine 3.7 (0.6–1.3mg/dl)
LDH 247 (100–190U/l)
Total protein 6.3 (6.4–8.2 g/dl)
Albumin 2.9 (3.4–5.0 g/dl)
Haptoglobin 268 (30–178mg/dl)
Iron 26 (35–150mcg/dl)
Iron binding capacity 235 (250–450mcg/dl)
Iron saturation% 11 (15–55%)
PTH 4.79 (11–67pg/ml)
PTH-RP o0.3 (0.0–1.5 pmol/l)
Vitamin B12 520 (193–982 pg/ml)
Folate 13.5 (3.0–17.0 ng/ml)
Vit D 1,25 91.3 (15.9–55.6 pg/ml)
Vit D 25-OH 56.3 (32.0–100.0 pg.ml)
BUN, blood urea nitrogen; LDH, lactate dehydrogenase; PTH, parathyroid hormone:
WBC, white blood cells.
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DISCUSSION
Light chain proximal tubulopathy, more commonly referred
to as light chain Fanconi syndrome (LCFS), is a rare pattern
of renal disease that occurs in the setting of dysproteinemia.
LCFS shares similarities with the more common entity of
myeloma cast nephropathy in that both conditions are
characterized by tubular injury with crystalline deposits of
monoclonal light chains. In LCFS, the crystalline deposits are
intracellular and confined to proximal tubules, as opposed to
the intraluminal, distal tubular casts seen in myeloma cast
nephropathy.1 As a result of crystal accumulation in proximal
tubules, patients with LCFS exhibit features of Fanconi
syndrome (i.e., proximal tubular dysfunction), including
normoglycemic glycosuria, aminoaciduria, uricosuria, hyper-
phosphaturia (with hypophosphatemia), and type II renal
tubular acidosis. In the case reported herein, testing for
Fanconi syndrome was not specifically performed and as
such, the terminology of ‘light chain proximal tubulopathy’ is
utilized. Nonetheless, the patient was noted to have
glycosuria in the setting of normal serum glucose.
LCFS is often a difficult diagnosis to establish based on
limited awareness of the entity, its relatively indolent
presentation in the majority of cases, and the subtle light
microscopic findings. Light microscopy typically reveals non-
specific findings of acute and chronic tubulointerstitial
nephropathy. The cytoplasm of proximal tubules contains
pale needle-shaped crystals that are mainly visible at high
power and may have a relatively localized distribution. The
crystals typically appear pale with the hematoxylin and eosin
and periodic acid Schiff stains, and often do not stain for k or
l light chain by standard IF on frozen tissue. As a result, the
diagnosis of LCFS may not be appreciated until ultrastruc-
tural evaluation, at which time abundant crystals of varying
appearance are identified within the cytoplasm of proximal
tubules. Interestingly, IF on formalin-fixed, paraffin-
embedded, pronase-digested tissue appears to be superior to
standard IF performed on frozen tissue for determining the
light chain composition of the proximal tubular crystals and
thus establishing the diagnosis of LCFS.2 This may relate to the
fact that pronase digestion has a denaturing effect on cell
membranes, which may unveil sequestered antigenic sites.
LCFS is a relatively rare form of renal disease with fewer
than 100 cases appearing in the medical literature, predomi-
nantly reported as isolated cases and small series. In 1975,
Maldonado et al.3 provided the first large series of LCFS,
presenting 3 new cases from the Mayo Clinic and reviewing the
findings in 14 previously published cases. In this initial
description, common characteristics included relatively
Figure 1 |Renal biopsy findings. (a) High power view of proximal tubules reveals pale-staining intracytoplasmic crystals (hematoxylin and
eosin,  600). (b) Immunofluorescence following pronase-digestion reveals intracellular crystals within proximal tubules which stain
positively for k light chain. Staining for l light chain is negative ( 400). (c) On ultrastructural evaluation, proximal tubular cells contain
intracytoplasmic crystalline inclusions ( 4000). (d) On high power inspection, the intracytoplasmic inclusions have a fibrillar appearance
and form parallel arrays. A minority of the inclusions lie in membrane-bound structures ( 8000).
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indolent renal dysfunction, Bence Jones proteinuria of k-type,
and in some cases, osteomalacia resulting from chronic
hypophosphatemia. Of note, in 11 of the 17 cases LCFS was
discovered before the development of MM or, less commonly,
amyloidosis. In the remaining 6 patients, the diagnosis of LCFS
and MM or amyloidosis was established simultaneously,
leading the authors to suggest that LCFS represents a precursor
to MM. In 2000, Messiaen et al.4 detailed 11 cases of LCFS and
emphasized the clinical heterogeneity of this entity. In this
series, clinical presentations ranged from acute renal failure to
more indolent renal dysfunction, a single patient presented
with osteomalacia, and multiple patients came to clinical
attention for bone pain that was subsequently found to relate
to lytic lesions of MM. Features of proximal tubular
dysfunction were identified in all 11 patients. In 2007, Kapur
et al.5 published a report of 5 cases of LCFS but broadened the
definition to include 3 cases in which electron microscopy only
revealed prominent phagolysosomes within tubular epithelia,
which were subsequently found to contain k light chains by
immuno-electron microscopy.
Fanconi syndrome is uncommon in adults and most often
signifies the presence of a plasma cell dyscrasia. A clinical
diagnosis of FS or a pathologic diagnosis of LCFS should
prompt a thorough hematologic work-up that may include
serum protein electrophoresis, urine protein electrophoresis,
Figure 2 |Diffuse large B-cell lymphoma of the Spleen. (a) The splenic parenchyma is replaced by medium-to-large lymphocytes with
round to ovoid nuclei, prominent nucleoli, and plasmacytoid morphology. Multiple apoptotic figures are seen (hematoxylin and eosin,
 400). (b) Immunohistochemical staining for CD20, a marker of B cells, is strongly positive in this diffuse large B-cell lymphoma ( 400).
(c and d) In situ hybridization of the neoplastic cells reveals diffuse k light chain mRNA expression (c). In situ hybridization for l light chain is
negative (d) ( 400,  400).
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serum free light chain testing, bone marrow biopsy, and
skeletal survey. The majority of reported cases of LCFS have
occurred in patients who have evidence of or later develop
MM or, less commonly, amyloidosis. There are also rare
reports of patients with LCFS in the setting of chronic
lymphocytic leukemia/small lymphocytic lymphoma.6,7 In
the case reported herein, LCFS was the result of k light chain
production by a large splenic mass of diffuse large B-cell
lymphoma. To our knowledge, this is the first report of
diffuse large B-cell lymphoma causing LCFS.
The propensity for the light chains in LCFS to form
crystals that precipitate within the cytoplasm of proximal
tubules appears to be determined by their amino acid
sequences and the resultant physical and chemical properties.
In the normal state, light chains pass through the GBM and
are reabsorbed by the proximal tubule where they are broken
down to amino acids by lysosomal enzymes. The first
reported characterization of a monoclonal k-cDNA from a
patient with LCFS was published by Aucouturier et al. in
1993. Sequencing of the k-cDNA showed that the variable
region exons most closely fit into the VK1 subgroup. Protease
treatment of the light chain produced an elongated NH2-
terminal fragment of the variable (V) domain that was
resistant to further degradation and was able to form crystals
when bound to itself or intact k light chains. It was
hypothesized that the unique properties of this VK1
subgroup light chain, namely its resistance to complete
proteolysis and its ability to form crystals, might explain the
proximal tubular crystal formation and FS seen in patients
with LCFS.8 A subsequent study by the same group compared
the protease resistance of light chains from 4 patients with
LCFS to 12 patients with myeloma cast nephropathy. In all 4
patients with LCFS, the light chains were of the VK1 subtype
and were partially resistant to proteolysis, producing a
12 kDa NH2-terminal fragment that was not further
degraded by pepsin or cathepsin B, which are principle
proteolytic lysosomal enzymes of the proximal tubules. In
contrast, the light chains from 12 patients with myeloma cast
nephropathy were susceptible to proteolytic digestion.9 On
the basis of these studies, the capacity to develop LCFS
appears to be (1) intrinsic to the light chain molecule; (2)
genetically determined as evidenced by common origin from
the VK1 subgroup; and (3) based on a physical property of
partial resistance to proteolysis, leading to the formation of a
truncated NH2-terminal fragment with a propensity to
crystallize. Analogous mechanisms of proteolytic resistance
and crystal formation are likely to underlie the infrequent
cases of LCFS associated with l light chain production.6,10
In 2006, Sirac et al.11 published a transgenic murine model
of LCFS which supported many of the existing concepts on
the pathogenesis of this condition. In this model, the mouse
JK region was replaced by the VK-JK gene from a patient with
LCFS. The mice developed LCFS with proximal tubular
crystals that appeared similar to what has been described in
the human condition, supporting the concept that the
development of LCFS is determined by the amino acid
sequence and resultant physicochemical properties of the
monoclonal light chain. When the human VK-JK expression
was conditionally deleted, tubular crystal formation was
dramatically reduced.
Prognosis and optimal therapy for LCFS remain largely
unknown. Although the majority of patients have relatively
indolent renal dysfunction, more precipitous development of
acute renal failure infrequently occurs. In the series of 11
patients reported by Messiaen et al.,4 four patients reached
the endpoint of doubling of creatinine or requirement for
dialysis. In 2004, Ma et al.12 reported the Mayo Clinic
experience with adult-acquired FS. Over a 35-year period, 32
patients were seen including 10 with MM, 6 with smoldering
MM, 2 with Waldenstrom’s macroglobulinemia, and 14 with
monoclonal gammopathy of undetermined significance
(MGUS). The mean creatinine in this cohort was 2.0mg/dl,
all patients had evidence of light chain Bence Jones
proteinuria (29 k; 3 l), and 69% had a monoclonal serum
protein. Importantly, only 17 patients underwent renal
biopsy, among which only 8 had crystals in proximal tubular
cells characteristic of LCFS. Thus, the data from this cohort
are reflective of a heterogeneous group that is not limited to
individuals with LCFS. Nonetheless, the findings are inter-
esting and noteworthy. Over the period of follow-up (mean
65 months), 5 patients progressed to ESRD, which in each
instance was more than 7 years after the initial diagnosis of
FS. The median time from diagnosis of FS to ESRD was 196
months, and only 1 of 10 patients with MGUS evolved to
MM. Chemotherapy was given to all patients with MM or
Waldenstrom’s macroglobulinemia, 4 of 6 patients with
smoldering MM, and 6 of 14 patients with MGUS. Among
the 10 patients with smoldering MM or MGUS who received
chemotherapy, no significant improvement in renal function
was seen over 4–26 months of treatment. Importantly, 4
patients (1 MGUS, 1 smoldering MM, 2MM) developed
treatment-related myelodysplastic syndrome or acute leuke-
mia and died. The authors concluded that the adult-acquired
FS has a slow progression to ESRD and that the risk of
chemotherapy with alkylating agents appears unjustified in
patients who lack evidence of overt malignancy. Again, it
must be pointed out that the majority of patients in this
series did not have biopsy-proven LCFS.
In summary, LCFS is a rare disease characterized by slowly
progressive renal dysfunction associated with FS. The
diagnosis of LCFS requires pathologic evaluation, where the
distinctive finding is accumulation of crystalline inclusions
composed of light chains within the cytoplasm of proximal
tubules. The monoclonal light chains are typically of k type
and are derived from the VK1 subgroup. These light chains
have the properties of resistance to proteolysis within
proximal tubules and a propensity to form intracellular
crystals. Patients with LCFS typically have evidence of MM,
‘smoldering MM,’ or MGUS, although rarely this condition
may be associated with B-cell non-Hodgkin lymphoma.
Although limited data are available, in patients who lack
evidence of overt malignancy, aggressive treatment with
796 Kidney International (2009) 76, 792–797
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alkylating agents does not appear justified. In cases of LCFS
with malignancy such as the one reported here, long-term
prognosis is likely to be closely tied to success in treating the
underlying malignancy.
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